Vol.

No.

July 17, 2026Jul 17, 2026

DOWNLOAD THE PDF

Cover Story

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way

Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

By Paul Goldberg and Claire Marie Porter

The United States has a translation problem. Scientific breakthroughs in oncology are accelerating, but clinical trial infrastructure hasn’t kept pace.

Regulatory News

FDA final guidance on psychedelics opens the door to psycho-oncology research
Guidance permits treatment without psychotherapy, alarming scientists, advocates

By Sara Willa Ernst

Regulatory News

OMB proposal to sideline peer review sparks widespread opposition
Nearly 500,000 public comments flood in—here are some highlights

By Claire Marie Porter

Guest Editorial

Cancer progress is not reaching everyone. Native Nations must be part of the solution.

By Rodney Haring

The future of oncology: Early-career scientists need mentorship and a new academic model

By Marcel van den Brink

Podcast

How will FDA regulate psychedelics?

Cancer Policy

House Energy & Commerce hearing focuses on America’s leadership in biomedical research, examines FDA role

White House regulatory priorities include “aggressive” HHS agenda

HHS cancels fourth USPSTF meeting in a row

In Brief

Dartmouth raises over $12M for cancer research at 45th annual Prouty fundraiser

RWJBarnabas Health, Rutgers Cancer opens Melchiorre Cancer Center

Fred Hutch Cancer Center announces 2026 Evergreen Fund awardees

LSU LCMC Health cancer center researchers receive $3.1M NIH grant to study pancreatic cancer

Karmanos Cancer Institute releases updated oncology clinical trials app

Funding Opportunities

Binaytara invites abstract applications for National Summit on Hematologic Cancers’ Hematologic Innovation Challenge

Clinical Roundup

Lenalidomide maintenance may end after two years for patients with MM, phase III trial finds

Digital check-ins improve outcomes for cancer patients, Alliance trial finds

Virtual smoking cessation program for patients with cancer doubles quitting rate in community oncology settings

Jemperli achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer, phase II study finds

Ris-Rez improves overall survival in SCLC, phase III trial finds

Experimental KRAS vaccine generates immune response against pancreatic cancer in people at high risk, phase I study finds

Study: 50 million Americans live in counties without a radiation oncology clinic

Insurance-supported integrative oncology program improves patients’ symptoms, Connor Whole Health and Case Western study finds

Drugs & Targets

FDA approves Padcev + Keytruda for muscle-invasive bladder cancer regardless of cisplatin eligibility

FDA approves Revtorpyk for HR+/HER2-, PIK3CA wild-type, locally advanced or metastatic breast cancer

FDA approves Sarclisa Escena for subcutaneous injection for multiple indications in MM

FDA approves companion diagnostic for Opdivo for ESCC and GEJ, gastric, and esophageal adenocarcinoma

FDA issues CRL for rivoceranib + camrelizumab as a first-line treatment for unresectable or metastatic HCC

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues